This is a recorded version of the AACC webinar Molecular Testing for MRSA and C. diff.: Using New Tools to Identify and Reduce HAIs, was originally held November 15, 2012. Healthcare-associated infections (HAIs) are one of the top 10 causes of death in the U.S., but efforts are underway at both the federal and state levels to track and reduce HAI rates across the country. Clinical labs can be helpful in these initiatives, particularly in
identifying methicillin-resistant Staphylococcus aureus (MRSA) and Clostridium difficile (C. diff.) infections. With molecular assays that significantly reduce the time needed to diagnose a MRSA or C. diff. infection recently entering the market, healthcare providers now have a variety of tests and methods to choose from when developing test protocols for surveillance programs or detecting an infection.
Clinical pathologists, molecular pathologists, microbiologists, MD and PhD laboratory directors, managers and supervisors, other clinical laboratory scientists, and IVD industry professionals involved in testing for MRSA or C. diff. infections.